Real-world study shows favorable efficacy-safety profile of dual targeted therapy in refractory PsA

Key clinical point: Dual targeted therapy (DTT) combining two biological disease-modifying antirheumatic drugs (bDMARD) or targeted synthetic (ts) DMARD led to satisfactory clinical improvements and no serious adverse events in patients with difficult-to-treat refractory psoriatic arthritis (PsA).

Major finding: At a median exposure of 14.86 months, the DTT retention rate in patients with PsA was 42.8%, with 40.0% and 53.3% of patients achieving remission or low activity and major clinical improvements, respectively. Treatment discontinuation due to adverse events was reported in one patient with PsA and multiple comorbidities.

Study details: Findings are from an observational, retrospective, cross-sectional study including patients with refractory PsA (n = 14) or spondyloarthritis (n = 22) who simultaneously received two bDMARD or tsDMARD with different therapeutic targets.

,

Disclosures: This study did not receive any funding. R García-Vicuña declared receiving educational grants, research grants, consultancies, speaking fees, or support for attending meetings from various sources.

Source: Valero-Martinez C et al. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: A real-world multicenter experience from Spain. Front Immunol. 2023;14:1283251 (Oct 23). doi: 10.3389/fimmu.2023.1283251